$CTMX has been discussed by 2 distinct FinTwit voices over a 12-month period, with 9 mentions total from November 2025 through March 2026. @jacobplieth dominates conversation with 11 mentions, while @adamfeuerstein contributed 1 mention. The biotech category accounts for discussion of CytomX Therapeutics' clinical programs, particularly regarding efficacy data and share performance metrics.